CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
- SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
- “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
- Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.
- Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).